Key result
CK2130 preserved initial circulating platelet counts and reduced the release of platelet factor 4 during simulated cardiopulmonary bypass.
Why the study?
Does phosphodiesterase inhibition with CK2130 or dipyridamole preserve platelets and reduce platelet activation during simulated cardiopulmonary bypass?
Does phosphodiesterase inhibition with CK2130 or dipyridamole preserve platelets and reduce platelet activation during simulated cardiopulmonary bypass?
Phosphodiesterase inhibitors such as CK2130 and dipyridamole preserve platelet counts and reduce platelet granule release during simulated cardiopulmonary bypass, suggesting a potential role in preventing surface-mediated thrombosis.
Answers are grounded in this paper and cite their sources.
May support PDE inhibition for platelet preservation in CPB; hypothesis-generating from animal data, human trials needed before practice change.
Inhibition of platelet function reduces adverse platelet alterations during cardiopulmonary bypass (CPB) but agents most efficacious must be given intravenously. Consequently, we evaluated a new type III phosphodiesterase inhibitor (PDEI), CK2130 (100 uM), comparing it with the most commonly prescribed oral PDEI, dipyridamole (100 uM). 450 ml of fresh heparinized (5U/ml) blood, drawn from aspirin-free volunteers, was recirculated for 2 hrs at 37°C in a polypropylene circuit (1.0m2) containing a spiral-coil membrane oxygenator. In control saline circuits (N=5), platelet counts fell to 10±3% (mean + standard error of the mean) of initial levels within 5 min and sensitivity to ADP disappeared. Plasma levels of a platelet-specific protein platelet factor 4 (PF4) rose from 2780±222 ng/ml at five minutes to 6338±767 ng/ml after 2 hrs (p < .05), indicating extensive platelet release. In contrast, with CK2130 (N=3), although platelets were similarly insensitive to ADP, platelet counts dropped to only 63±11% at five minutes and PF4 rose from 1012±510 ng/ml at five minutes to only 3689± 898 ng/ml after 2 hrs (p < .05). With dipyridamole (N=4) platelet counts fell to 66±7% and PF4 rose from 861±122 ng/ml at five minutes to only 2157±346 ng/ml after 2 hrs (p <.05) but platelets remained responsive to ADP. In conclusion, both CK2130 and dipyridamole significantly preserved the initial circulating platelet count and reduced release of PF4 with CK2130 producing more pronounced inhibition of function as well. Thus, PDEIs may play a promising role as platelet inhibitors during CPB.
No takes yet. Share an insight, caveat, or question.
Stenach et al. (1989) studied Simulated cardiopulmonary bypass (n=12). CK2130 vs. Saline and dipyridamole (100 uM) was evaluated on Platelet count at 5 minutes (% of initial). CK2130 preserved initial circulating platelet counts and reduced the release of platelet factor 4 during simulated cardiopulmonary bypass.
Synapse has enriched 10 related papers. Consider them for comparative context: